Another phase III study (KEYNOTE-042 study) of 1274 patients with unresectable advanced or recurrent NSCLC with PD-L1 TPS ≥ 1% showed that pembrolizumab monotherapy significantly prolonged OS compared to platinum-containing chemotherapy (5). Here, CD274 is linked to non-small cell lung carcinoma.